What is Bristol-Myers Squibb Company (BMY)?

Bristol-Myers Squibb Company (BMY) is a stock in the Healthcare sector, Drug Manufacturers - General industry. View full analysis on Stocks360.

What is the current price of BMY?

The current price of BMY is $61.55. Prices are updated in real time on Stocks360.

What is BMY's price-to-earnings (PE) ratio?

BMY's trailing twelve-month PE ratio is 13.56, based on current price and earnings per share data available on Stocks360.

What is BMY's market capitalization?

BMY's market capitalization is $125,728,800,500.00, placing it in the large-cap tier.

Does BMY pay a dividend?

Yes. BMY has a trailing twelve-month dividend yield of 0.04%. Dividend data is sourced from financial market providers and displayed on Stocks360.

Bristol-Myers Squibb Company (BMY)

Stock analysis · NYSE · Healthcare · Drug Manufacturers - General

$61.55

Market Cap

$125.73B

PE (TTM)

13.56

EPS (TTM)

N/A

Dividend Yield

4.09%

Beta

0.23

Day Range

$60.92 – $61.64

52-wk Range

$42.52 – $68.64

Avg Volume

N/A

Volume

7.75M

Bristol-Myers Squibb Company (BMY) is a publicly traded company in the Healthcare sector. Latest price: $61.55. Market cap $125.73B. Trailing PE 13.56. Dividend yield 4.09%. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $42.82 2026-10-27 · $61.55 (+43.74%)

Earnings

Most Recent

Jul 30, 2026

EPS $2.04 vs est. $1.60

Beat by $0.44

Next Earnings

Oct 29, 2026

EPS estimate $1.10

Proprietary Signals

Signal snapshot temporarily unavailable.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offe…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	13.56×
P/S (TTM)	2.56×
P/B	5.63×
PEG	0.16×
P/FCF (TTM)	10.99×
EV / EBITDA	9.52×
EV / Sales	3.26×
Earnings Yield	7.39%
Free Cash Flow Yield	9.10%
Dividend Yield	4.09%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$160.13B
Revenue (TTM)	$49.19B
Net Income (TTM)	$9.29B
Free Cash Flow (TTM)	$12.79B
Net Debt	$34.40B
Working Capital	$9.92B
Gross Margin	70.16%
Operating Margin	28.14%
Net Margin	18.87%
Return on Equity	46.75%
Return on Invested Capital	15.40%